The FDA approved a phase 3 trial for amezalpat with Tecentriq and Avastin in hepatocellular carcinoma treatment. Amezalpat targets tumor cells and modulates the tumor microenvironment, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results